ES2616258T3 - Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna - Google Patents

Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna Download PDF

Info

Publication number
ES2616258T3
ES2616258T3 ES11712343.0T ES11712343T ES2616258T3 ES 2616258 T3 ES2616258 T3 ES 2616258T3 ES 11712343 T ES11712343 T ES 11712343T ES 2616258 T3 ES2616258 T3 ES 2616258T3
Authority
ES
Spain
Prior art keywords
immunogenicity
conjugates
vaccine
peptides
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11712343.0T
Other languages
English (en)
Inventor
Ferdinand Antonius Ossendorp
Cornelis Joseph Maria Melief
Jan Wouter Drijfhout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STICHTING TECHNISCHE WETENSCHAPPEN
Stichting voor de Technische Wetenschappen STW
Leids Universitair Medisch Centrum LUMC
Original Assignee
STICHTING TECHNISCHE WETENSCHAPPEN
Stichting voor de Technische Wetenschappen STW
Leids Universitair Medisch Centrum LUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STICHTING TECHNISCHE WETENSCHAPPEN, Stichting voor de Technische Wetenschappen STW, Leids Universitair Medisch Centrum LUMC filed Critical STICHTING TECHNISCHE WETENSCHAPPEN
Application granted granted Critical
Publication of ES2616258T3 publication Critical patent/ES2616258T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un conjugado, que comprende un péptido conjugado con un antígeno, inmunógeno o con un vehículo que comprende un antígeno o inmunógeno, en el que el péptido consiste en la secuencia de aminoácidos de una cualquiera de SEQ ID NO: 8, 9, 12, 13, 16, 17, 19-24, 151-158, 163-166, 168, 172-176, 179-182, 185-197, 198-208 y 210-216, y en el que el antígeno, el inmunógeno o el vehículo que comprende el antígeno o inmunógeno está conjugado con el extremo C terminal del péptido.
ES11712343.0T 2010-03-15 2011-03-15 Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna Active ES2616258T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10156505 2010-03-15
EP10156505 2010-03-15
US31793010P 2010-03-26 2010-03-26
US317930P 2010-03-26
PCT/NL2011/050180 WO2011115483A1 (en) 2010-03-15 2011-03-15 Peptides, conjugates and method for increasing immunogenicity of a vaccine

Publications (1)

Publication Number Publication Date
ES2616258T3 true ES2616258T3 (es) 2017-06-12

Family

ID=43430699

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11712343.0T Active ES2616258T3 (es) 2010-03-15 2011-03-15 Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna

Country Status (15)

Country Link
US (1) US9522962B2 (es)
EP (1) EP2547364B1 (es)
CN (1) CN102892431A (es)
CA (1) CA2793087C (es)
CY (1) CY1118801T1 (es)
DK (1) DK2547364T3 (es)
ES (1) ES2616258T3 (es)
HR (1) HRP20170251T1 (es)
HU (1) HUE031924T2 (es)
LT (1) LT2547364T (es)
PL (1) PL2547364T3 (es)
PT (1) PT2547364T (es)
RS (1) RS55670B1 (es)
SI (1) SI2547364T1 (es)
WO (1) WO2011115483A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2946010B1 (en) 2013-01-18 2018-08-29 London School of Hygiene and Tropical Medicine Glycosylation method
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
EP3119432B1 (en) * 2014-03-19 2020-01-08 MacKay Medical Foundation the Presbyterian Church in Taiwan MacKay Memorial Hospital Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
CN106986923B (zh) * 2017-04-10 2021-01-26 新疆农垦科学院 GnRH抗原及其在主动免疫对公牛的去势效果及肉品质影响中的应用
MX2020010621A (es) 2018-04-10 2020-10-20 Ac Immune Sa Vacunas terapeuticas anti-abeta.
EP3830110A4 (en) * 2018-07-31 2022-03-02 Snoretox Pty Ltd PEGYLATED TETANUS NEUROTOXINS AND THE TREATMENT OF HYPOTONIA
WO2020104690A1 (en) 2018-11-23 2020-05-28 Quine Medical Ab Bi-specific conjugates
GB201917699D0 (en) 2019-12-04 2020-01-15 Ultimovacs Ab Vaccine conjugates
US20230057367A1 (en) * 2020-02-03 2023-02-23 Snoretox Ltd Composition and method
CN113318225B (zh) * 2020-02-28 2024-01-19 无锡派列博生物医药科技有限公司 肿瘤免疫增强剂及其制法和应用
GB202008003D0 (en) 2020-05-28 2020-07-15 Quine Medical Ab Anti-CD40 antibody
WO2022087122A1 (en) * 2020-10-20 2022-04-28 Longhorn Vaccines And Diagnostics, Llc Immunogenic antigens
EP4301406A1 (en) * 2021-03-04 2024-01-10 Longhorn Vaccines and Diagnostics, LLC Vaccines for the treatment and prevention of zoonotic infections
EP4351634A2 (en) * 2021-06-09 2024-04-17 Ultimovacs AB A conjugate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0737205A1 (en) * 1993-12-28 1996-10-16 Chiron Mimotopes Pty. Ltd. T-cell epitopes
JP4229341B2 (ja) * 1996-03-23 2009-02-25 財団法人阪大微生物病研究会 破傷風毒素の機能的フラグメント抗原及び破傷風ワクチン
EP0971747B1 (en) 1996-10-28 2005-12-28 Amersham Health AS Contrast agents
US6180084B1 (en) 1998-08-25 2001-01-30 The Burnham Institute NGR receptor and methods of identifying tumor homing molecules that home to angiogenic vasculature using same
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
US6372250B1 (en) 2000-04-25 2002-04-16 The Regents Of The University Of California Non-invasive gene targeting to the brain
CA2431500C (en) 2000-12-08 2016-06-07 Sjoerd Hendrikus Van Der Burg Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
US20040101534A1 (en) 2002-06-25 2004-05-27 Diamond Don J. Adjuvant-free peptide vaccine
US9662383B2 (en) 2007-03-26 2017-05-30 University Of Massachusetts Compositions and methods for increasing immunogenicity of glycoprotein vaccines

Also Published As

Publication number Publication date
EP2547364B1 (en) 2016-12-14
LT2547364T (lt) 2017-03-27
RS55670B1 (sr) 2017-06-30
SI2547364T1 (sl) 2017-05-31
US20130071428A1 (en) 2013-03-21
HUE031924T2 (en) 2017-08-28
DK2547364T3 (en) 2017-02-27
CN102892431A (zh) 2013-01-23
CA2793087A1 (en) 2011-09-22
CA2793087C (en) 2019-07-23
HRP20170251T1 (hr) 2017-04-21
PL2547364T3 (pl) 2017-06-30
CY1118801T1 (el) 2018-01-10
EP2547364A1 (en) 2013-01-23
US9522962B2 (en) 2016-12-20
PT2547364T (pt) 2017-02-21
WO2011115483A1 (en) 2011-09-22

Similar Documents

Publication Publication Date Title
ES2616258T3 (es) Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna
ES2539812T3 (es) Péptidos derivados de PRAME y composiciones inmunogénicas que comprenden los mismos
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
NZ618391A (en) Antigenic tau peptides and uses thereof
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
CL2013003416A1 (es) Secuencia de peptidos quiméricos que comprende dsspl o dasph composiciones , usos y metodo para mejorar metabolismo de glucosa.
CO6470802A2 (es) Péptido auxiliar del antígeno del cáncer
GB2465733A (en) Influenza entigen delivery vectors and constructs
PE20121393A1 (es) Analogo peptidico de oxintomodulina
PE20210376A1 (es) Peptidos y combinacion de peptidos de origen no canonico para el uso en la inmunoterapia contra diferentes tipos de cancer
UA118167C2 (uk) Пептид та його застосування
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
CY1116646T1 (el) Αντικαρκινικη πρωτεϊνη συντηξης
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
NZ604089A (en) Multivalent glycopeptide constructs and uses thereof
PE20240825A1 (es) Anticuerpos anti-c5 y metodos de uso
AR078374A1 (es) Peptidos aislados de veneno de arana y sus usos como potentes y selectivos bloqueadores del canal ionico
PE20201067A1 (es) Anticuerpos anti-csf 1r
EA201491277A1 (ru) Противораковый слитый белок
AR100768A1 (es) Método para disminuir la inmunogenicidad de proteínas y péptidos
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии
MY167069A (en) Antigen peptide and use thereof
AR083766A1 (es) Peptido inmunogenico
AR080621A1 (es) Uso de una fuente de l3 y/o l5 como vacuna o como diagnostico para una enfermedad parasitaria
MX2022008298A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.